PHI-1’s role as a cancer driver directly translates into its clinical implications, serving as both a biomarker for tumor aggressiveness and therapy resistance as well as a potential therapeutic target across multiple cancer types (Table 1). This evidence concerns the gene PPP1R14B and neoplasm.